Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For people with suspected or confirmed esophageal cancer (Group 1):

• Adults aged 18 or older at the time of their screening visit.
• People currently receiving care at Muhimbili National Hospital (MNH-Upanga or MNH-Mloganzila) in Tanzania.
• People who have already had a confirmed diagnosis of esophageal squamous cell cancer (a specific type of throat/food pipe cancer), OR people who are scheduled for a camera procedure and tissue sample (EGD with biopsy) because esophageal cancer is suspected based on scan results, symptoms like difficulty swallowing or painful swallowing, or other test findings.
• People who are able to swallow liquids (confirm with trial site).
• People who are well enough to take part in a 20-minute interview, or who have a close family member who could do this on their behalf.
• People who are willing to be contacted in person or by phone 7–10 days after using a small swallowable sponge device called the 'EsophaCap'.
• People who are originally from Tanzania.
• People who have given written consent to participate, or whose legal representative has done so on their behalf.

For people without suspected esophageal cancer (Group 2):

• Adults aged 18 or older at the time of their screening visit.
• People currently receiving care at MNH-Upanga or MNH-Mloganzila in Tanzania.
• People scheduled for a camera procedure (EGD) for a suspected non-cancerous condition, with no symptoms suggesting esophageal cancer such as difficulty swallowing or painful swallowing.
• People who are able to swallow liquids (confirm with trial site).
• People who are well enough to take part in a 20-minute interview, or who have a close family member who could do this on their behalf.
• People who are willing to be contacted in person or by phone 7–10 days after using the 'EsophaCap' sponge device.
• People who are originally from Tanzania.
• People who have given written consent to participate, or whose legal representative has done so on their behalf.

Who may not be able to join:

For people with suspected or confirmed esophageal cancer (Group 1):

• People who are known to be pregnant during the study.
• People with a condition that the study doctor believes could put their safety at risk or affect the quality of the study results.
• People who are medically unstable, for example those with very low blood pressure or a recent heart event.
• People who have had any bleeding in their upper digestive tract (such as vomiting blood or black stools) in the past 3 months.
• People diagnosed with a stomach ulcer (peptic ulcer disease) within the last 3 months.
• People with a known history of swollen veins in the food pipe (esophageal varices).
• People taking blood-thinning or anti-clotting medications (such as warfarin, clopidogrel, aspirin, heparin, or enoxaparin) for serious health conditions.
• People with an active cancer elsewhere in the body (not in remission) other than esophageal cancer.
• People with a known history of a non-cancerous narrowing of the food pipe (esophageal stricture).
• People who currently have a stent (a small tube) placed in their food pipe.
• People who have previously had radiation therapy to the head, neck, chest, or any part of the digestive tract including the food pipe.
• People who have received chemotherapy in the last 12 months.
• People who have had major surgery related to esophageal cancer, such as removal or bypass of the food pipe.
• People with a known or suspected abnormal connection between the food pipe and the airway (tracheoesophageal fistula), including those with a history of inhaling food or liquid, or severe coughing.
• People with a known history of blockage of the small bowel (small bowel obstruction).
• People who have experienced bleeding complications during a previous food pipe biopsy.
• People with any history of cancer of the head or neck.
• People with a known bleeding disorder.
• People with a known low platelet count (fewer than 50,000 platelets per microlitre of blood).
• People who are not permanent residents or natives of Tanzania.
• People who are unable to follow study instructions.
• People who are unable to give informed consent.

For people without suspected esophageal cancer (Group 2):

• People who are known to be pregnant during the study.
• People with a condition that the study doctor believes could put their safety at risk or affect the quality of the study results.
• People who are medically unstable, for example those with very low blood pressure or a recent heart event.
• People who have had any bleeding in their upper digestive tract in the past 3 months.
• People diagnosed with a stomach ulcer (peptic ulcer disease) within the last 3 months.
• People with a known history of swollen veins in the food pipe (esophageal varices).
• People taking blood-thinning or anti-clotting medications (such as warfarin, clopidogrel, aspirin, heparin, or enoxaparin) for serious health conditions.
• People with an active cancer elsewhere in the body that is not in remission, or any history of a non-skin cancer diagnosed within the last five years.
• People with a known narrowing of the food pipe severe enough to prevent a small capsule from passing through.
• People who currently have a stent placed in their food pipe.
• People who have previously had radiation therapy to the head, neck, chest, or any part of the digestive tract including the food pipe.
• People with a known history of blockage of the small bowel.
• People with a known bleeding disorder.
• People with a known low platelet count (fewer than 50,000 platelets per microlitre of blood).
• People who are not permanent residents or natives of Tanzania.
• People with a known allergy to iodine.
• People with a known enlarged thyroid gland (goiter).
• People who are unable to follow study instructions.
• People who are unable to give informed consent.

Important: Always verify eligibility with the trial site directly before applying.